洛之达和舒降之对原发性高胆固醇血症的临床疗效比较  

A Clinical Study on Efficacy of Luozhida and Zocor in Patients with Hypercholesterolemia

作　　者：叶平[1] 尚延中[1] 刘秀云[1] 司全金[1] 

机构地区：[1]解放军总医院老年心内科

出　　处：《中国动脉硬化杂志》1999年第1期65-67,共3页Chinese Journal of Arteriosclerosis

摘　　要：为比较洛之达和舒降之的调脂强度，将６３例原发性高胆固醇血症患者随机分为洛之达组和舒降之组，观察服药前及服药后４周，８周血脂水平的变化。结果发现，服药４周、８周末，洛之达组和舒降之组血清总胆固醇、低密度脂蛋白胆固醇和载脂蛋白Ｂ均较治疗前有显著性降低（Ｐ＜０．０１）。洛之达降胆固醇的强度较舒降之弱。用药后两组甘油三酯水平显著降低（Ｐ＜０．０５），高密度脂蛋白胆固醇趋于升高，但无统计学意义，服药８周末洛之达组载脂蛋白ＡＩ显著升高（Ｐ＜０．０１）。患者对洛之达和舒降之的耐受性良好，无明显不良反应。结论提示，舒降之和洛之达可有效调节脂质代谢紊乱，洛之达是一种安全有效的国产血脂调节剂。Aim The present study was to compare the lipid lowering efficacy of Luozhida (lovastatin) with zocor (simvastatin). Methods 63 subjects were randomized into two groups: 31 subjects in luozhida group, 32 subjects in zocor group as controls.Blood lipid levels were determined prior to lipid lowering treatment and at the end of 4 and 8 week treatment respectively. Results At the end of 8 week treatment, levels of TC, LDLC and apolipoprotein B in luozhida group and zocor group significantly reduced (P<0.01). The LDL cholesterol lowering efficacy of luozhida was significantly weaker than that of zocor. TG level was also significantly lower after treatment compared with that prior to treatment in both groups (P<0.05). At the end of 8 week treatment HDLC level tended to be higher in both group, though the difference was not statistically significant, while apolipoprotein AI level obviously increased in the luozhida group. There was no obvious side effects during the period of luozhida and zocor treatment and the patient's tolerance was good. Conclusion Luozhida, as a domestically made lipid lowering drug,is effective for the treatment of hypercholesterolemia.

关 键 词：高胆固醇血症 洛伐他丁 辛伐他丁 

分 类 号：R589.205[医药卫生—内分泌]